Reply: Incidence and Risk Factors for Development of Thrombocytopenia in Patients Treated With Linezolid for 7 Days or Greater

Abstract

Get full access to this article

View all access options for this article.

References

Giunio-Zorkin

Brown

Comment: Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater. Ann Pharmacother. 2019;53:219. doi:10.1177/1060028018783498

Hirano

Sakamoto

Tachibana

Ohnishi

Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36:795-799.

Ichie

Suzuki

Yasui

et al . The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis. J Clin Pharm Ther. 2015;40:279-284.

Takahashi

Takesue

Nakajima

et al . Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17:382-387.

Hanai

Matsuo

Ogawa

et al . A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22:536-542.

Chen

Guo

Cao

et al . Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73:195-206.

Hui

Cook

Lim

Fraser

Arnold

DM.

The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. 2011;139:271-278.

Greinacher

Selleng

How I evaluate and treat thrombocytopenia in the intensive care unit patient. Blood. 2016;128:3032-3042.